Evidence map›Paper›PMID 40974572›Full record

ArticleCell reports2025

CD7 regulates the persistence of terminally exhausted CD8

Sean Hyslop, Colby J Hofferek, Maria V Stegantseva, Emerald Kan, Kelli A McCord, Victor M Alvarez, Amanda Y Xia, Jacob P Conarty, Andreas Wieland, William H Hudson

Abstract read
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. 5-FU chemotherapy induces functional CD7Science China. Life sciences · 2026
    Article
  3. Article
  4. Splenic PD-L1Research (Washington, D.C.) · 2026
    Article
  5. Multimodal analysis definesbioRxiv : the preprint server for biology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sean HyslopDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA; Medical Scientist Training Program, Baylor College of Medicine, Houston, TX 77030, USA.
Colby J HofferekDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Maria V StegantsevaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Emerald KanDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Kelli A McCordDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Victor M AlvarezDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Amanda Y XiaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA; Medical Scientist Training Program, Baylor College of Medicine, Houston, TX 77030, USA.
Jacob P ConartyDepartment of Otolaryngology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Andreas WielandDepartment of Otolaryngology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
William H HudsonDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: william.hudson@bcm.edu.

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
Training In Cell and Gene TherapyT32HL092332 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI MALCOLM K. BRENNER, Bruno Di Stefano · 2008 to 2026
$6.9M
Engineering bZIP family transcription factors for therapeutic T-cell persistence and effector functionR37CA285289 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Glenna Wink Foight · 2024 to 2026
$1.5M
Control of CD8+ T cell exhaustion by novel checkpoint moleculesR00AI153736 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI HUDSON, WILLIAM HARRIS · 2022 to 2023
$498k
BD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430k
NCI NIH HHS P30 CA125123NCI NIH HHS R37 CA285289NCRR NIH HHS S10 RR024574NHLBI NIH HHS T32 HL092332NIAID NIH HHS R00 AI153736
6 · The paper itself

Abstract

CD8

Indexed as

CD8-Positive T-LymphocytesPersistent InfectionAnimalsApoptosisHumansLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorSignal TransductionProgrammed Cell Death 1 ReceptorCD7CD8 T cellCP: ImmunologyimmunologyLCMVscRNA-seqT cellT cell exhaustionviral immunology

Identifiers

PMID40974572
PMCPMC12509300

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.